

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Aroa Biosurgery Limited
ARBN	638 867 473

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brian Ward
Date of last notice	27 July 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	31 March 2023
No. of securities held prior to change	Indirect <u>Mr Brian Ward & Mrs Tracey Ward <Arawai No 2 /C></u> 33,125,800 Fully Paid Ordinary Shares 3,132,525 Options exercisable at \$0.75 expiring 23 July 2025
Class	1. Options exercisable at \$Nil expiring 13 November 2027 (issued 28/11/22) 2. Options exercisable at \$1.165 expiring on 13 November 2027 (issued 28/11/22) 3. Options exercisable at \$1.165 expiring 29 February 2028 4. Options exercisable at \$Nil expiring 29 February 2028

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	1. 1,217,610 2. 649,695 3. 254,972 4. 453,206
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	Indirect <u>Mr Brian Ward & Mrs Tracey Ward <Arawai No 2 A/C></u> 33,125,800 Fully Paid Ordinary Shares 3,132,525 Options exercisable at \$0.75 expiring 23 July 2025 1,217,610 Options exercisable at \$Nil expiring 13 November 2027 649,695 Options exercisable at \$1.165 expiring on 13 November 2027 254,972 Options exercisable at \$1.165 expiring 29 February 2028 453,206 Options exercisable at \$Nil expiring 29 February 2028
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued on 31 March 2023 pursuant to shareholder approval received at the Annual General Meeting held on 10 August 2022

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	-
Interest acquired	-
Interest disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	-

+ See chapter 19 for defined terms.

Interest after change	-
-----------------------	---

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.